ABBV and JNJ Related Headlines
Go Back- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
- HSBC lists 11 potential U.S. outperformers heading into earnings
- Trump to announce prescription drug price agreements
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Buy this U.S. large-cap biopharma stock: JPMorgan
- Trump demands pharma CEOs lower drug prices within 60 days
- Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
- Lawmakers push to ban direct-to-consumer drug advertising, WSJ reports
ABBV and JNJ Related Press Releases
Go Back- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
